Evidence-based·Updated November 19, 2026·How we grade evidence

Methylene Blue

MedicationDye and medicine (the approved form is a prescription injection)

Methylene blue is an approved injection for methemoglobinemia, given in hospital. Taking it by mouth for focus, memory, mood or longevity is not an approved use: human evidence is limited to a few small trials, including a single-dose brain-scan study in 26 healthy adults and small studies in bipolar depression, and a large trial of a related compound in Alzheimer's disease was negative. It carries a boxed warning for serotonin syndrome with antidepressants and opioids, and it can destroy red blood cells in G6PD deficiency.

Taking Methylene Blue with other supplements or medications?Check your whole list for interactions. Free, no account.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults and children with acquired methemoglobinemia, treated with the intravenous product by a healthcare provider

Common dosing range

Your prescriber sets the dose. The ProvayBlue label: 1 mg/kg intravenously over 5 to 30 minutes, with one repeat dose of up to 1 mg/kg an hour later if needed. There is no approved oral dose

When to expect effects

In the label's studies, 26 of 28 adults had methemoglobin cut by at least half at the first check after treatment (median 2.7 hours after the infusion)

Watch out for

Boxed warning: serious or fatal serotonin syndrome when used with SSRIs, SNRIs, MAOIs and opioids. Contraindicated in G6PD deficiency (risk of severe hemolytic anemia) and in severe allergy to methylene blue or other thiazine dyes. Oral products sold online are not FDA-approved and their strength and purity are unverified

What is it

Methylene blue (methylthioninium chloride) is a blue dye that is also a prescription medicine. In the US it is FDA-approved only as an injection into a vein: ProvayBlue and generic methylene blue injections treat acquired methemoglobinemia, a condition in which too much hemoglobin is changed into a form that cannot carry oxygen, in adults and children. A healthcare provider gives it, usually in a hospital. Every methylene blue approval listed in Drugs@FDA (checked November 2026) is an intravenous solution. The drops, capsules and powders sold online as a "biohacking", brain or energy supplement are not FDA-approved drugs. It also appears in some older urinary antiseptic tablets (for example Urelle and Uribel), which DailyMed lists as "unapproved drug other".

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have acquired methemoglobinemia and your care team gives it intravenously
You are interested in brain or mood effects and can join a registered clinical trial, or want to discuss approved options with your doctor

Probably skip if…

You take an SSRI, SNRI, MAOI or opioid (boxed warning), or bupropion, buspirone, clomipramine, mirtazapine, linezolid or dextromethorphan: the label says to avoid these combinations because of possibly fatal serotonin syndrome
You have G6PD deficiency (contraindicated) or have not been tested and have a family history of it
You are pregnant or breastfeeding and thinking of using it outside medical care: the label says it may cause fetal harm, should be used in pregnancy only if the potential benefit justifies the potential risk, and that breastfeeding should stop for up to 8 days after treatment
You want a proven memory, energy or anti-aging supplement: no oral product sold online is approved, and the human trials are small and short

Evidence at a glance

Alzheimer's disease (LMTM, a related compound, not methylene blue itself)

Good Evidence
Effect
None on the main measures of the largest completed trial
Best fit
Not established
Time
Measured over 15 months

bipolar depression, added to other treatment (off-label)

Limited Evidence
Effect
Moderate improvement in depression and anxiety scores in small trials
Best fit
Adults with bipolar disorder on mood stabilizers, under specialist care
Time
Months; measured over 6 months to 2 years

delirium after surgery in older adults (off-label, intravenous)

Limited Evidence
Effect
Large in one trial; delirium 8.3% vs 20.4%
Best fit
Older adults having joint replacement under anesthesia
Time
Measured over 5 days after surgery

memory and attention in healthy adults (off-label)

Mixed Evidence
Effect
Small; 7% more correct answers on one memory task, plus changes in brain-scan activity
Best fit
Healthy adults in a laboratory study
Time
Measured 1 hour after a single dose

fear extinction in claustrophobia and PTSD therapy (off-label)

Mixed Evidence
Effect
Mixed; helped only when therapy sessions went well, and possibly harmful when they did not
Best fit
Adults in exposure-based therapy within a research setting
Time
Measured 1 to 3 months after brief therapy

Evidence for 5 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

Alzheimer's disease (LMTM, a related compound, not methylene blue itself)

No benefit found
Good Evidence

Not an approved use, and not methylene blue itself: this trial tested LMTM, a related compound. In a 15-month phase 3 trial in 891 people with mild to moderate Alzheimer's disease in 16 countries, LMTM (a stable reduced form of methylthioninium, the active part of methylene blue) at 75 mg or 125 mg twice daily did not slow decline on either main measure of memory and thinking or daily function compared with a control dose of 4 mg twice daily. An earlier phase 2 trial of methylthioninium chloride (methylene blue) in 321 people suggested benefit at 138 mg a day, and a 2026 phase 3 trial of hydromethylthionine could not show differences on its main measures at 52 weeks (the authors attributed this to effects in the control group), reporting differences in mild cognitive impairment only at 78 and 104 weeks. The 15-month phase 3 trial was funded by the developer, TauRx Therapeutics.

Effect size
None on the main measures of the largest completed trial
Time to effect
Measured over 15 months
Best fit
Not established
Less likely
People with mild to moderate Alzheimer's disease, the group studied, and healthy people using online products, who were never studied

Bottom line: The largest completed trial of LMTM, a compound related to methylene blue, did not slow Alzheimer's disease.

Evidence is mixed

A phase 2 trial of methylthioninium chloride reported benefit at 138 mg a day, and a 2026 phase 3 trial of hydromethylthionine reported late differences in mild cognitive impairment, but the coprimary outcomes of the large phase 3 trials were not met at their prespecified time points.

bipolar depression, added to other treatment (off-label)

Disease adjunct
Limited Evidence

Off-label use. In a 6-month double-blind crossover trial, 37 people with bipolar disorder already taking lamotrigine received methylene blue 195 mg a day or a 15 mg comparison dose. The higher dose improved depression scores (MADRS, P = 0.02) and anxiety scores (P = 0.02), mania stayed low, and cognitive test results did not improve. A 1986 two-year crossover trial in 31 people on lithium (17 completed) found less depression on 300 mg a day than on 15 mg, but the authors noted many dropouts and doubts about blinding.

Effect size
Moderate improvement in depression and anxiety scores in small trials
Time to effect
Months; measured over 6 months to 2 years
Best fit
Adults with bipolar disorder on mood stabilizers, under specialist care
Less likely
People taking SSRIs, SNRIs or other serotonergic antidepressants, for whom the combination carries a boxed warning

Bottom line: Two small trials suggest an add-on effect on bipolar depression; it has not been confirmed or approved.

delirium after surgery in older adults (off-label, intravenous)

Disease adjunct
Limited Evidence

Off-label use, given intravenously in an operating room, not by mouth. In a randomized trial of 217 adults aged 60 or older having joint replacement, an infusion of 2 mg/kg methylene blue during anesthesia lowered delirium in the 5 days after surgery from 20.4% to 8.3% (hazard ratio 0.39). Fever after surgery was more common with methylene blue (16.5% vs 7.4%).

Effect size
Large in one trial; delirium 8.3% vs 20.4%
Time to effect
Measured over 5 days after surgery
Best fit
Older adults having joint replacement under anesthesia
Less likely
Anyone taking oral products at home, which this trial did not study

Bottom line: One trial found an intravenous dose during surgery cut post-operative delirium; it says nothing about oral supplements.

memory and attention in healthy adults (off-label)

Biomarker support
Mixed Evidence

Off-label use. In a double-blind, placebo-controlled trial, 26 healthy adults aged 22 to 62 had brain scans (functional MRI) during attention and short-term memory tasks before and 1 hour after a single low dose of methylene blue by mouth or placebo. Methylene blue increased brain activity in several regions during the tasks and was associated with a 7% increase in correct answers during memory retrieval. It was one dose, in one small group, measured once; it did not test daily use, the products sold online, or any long-term outcome.

Effect size
Small; 7% more correct answers on one memory task, plus changes in brain-scan activity
Time to effect
Measured 1 hour after a single dose
Best fit
Healthy adults in a laboratory study
Less likely
Anyone taking serotonergic medicines or with G6PD deficiency, who were not the population and face serious risks

Bottom line: One small single-dose study hints at a short-term memory effect; it is far from proof of a brain supplement.

fear extinction in claustrophobia and PTSD therapy (off-label)

Disease adjunct
Mixed Evidence

Off-label use. In 42 adults with marked claustrophobia, a single 260 mg dose of methylene blue after an exposure session led to less fear a month later only in those whose fear had dropped during the session; those still very afraid at the end tended to do worse than with placebo. In a trial of 42 people with chronic PTSD, 260 mg was given after 5 daily imaginal exposure sessions. Both the methylene blue and placebo groups improved strongly and did not differ from standard prolonged exposure therapy at 3 months, although methylene blue improved evaluator-rated treatment response and quality of life compared with placebo.

Effect size
Mixed; helped only when therapy sessions went well, and possibly harmful when they did not
Time to effect
Measured 1 to 3 months after brief therapy
Best fit
Adults in exposure-based therapy within a research setting
Less likely
People taking it on their own without therapy, which was not studied

Bottom line: Small studies give mixed results, with a possible downside after unsuccessful therapy sessions.

How it works

In the body, methylene blue is converted by an enzyme that needs NADPH into leucomethylene blue, which turns methemoglobin back into normal hemoglobin. This is why people with G6PD deficiency, who make less NADPH in their red blood cells, may not respond and can develop severe destruction of red blood cells (hemolysis). The label also says literature reports suggest methylene blue is a potent reversible inhibitor of monoamine oxidase (MAO), the enzyme that breaks down serotonin. That is the reason for its boxed warning: combined with serotonergic medicines, it can cause serotonin syndrome. The interest in brain effects comes from laboratory work showing that low doses can pass electrons along the mitochondrial chain that cells use to make energy. In people, only a handful of small trials have tested memory or mood, mostly single doses or a few months of treatment, and none tested the products sold online.

How to take it

1. Typical dose
Your prescriber sets the dose, and it is given by a healthcare provider. The ProvayBlue label: 1 mg/kg intravenously over 5 to 30 minutes. If methemoglobin stays above 30% or symptoms continue, a repeat dose of up to 1 mg/kg may be given one hour after the first; if it has not resolved after 2 doses, other treatments are considered. People with moderate or severe kidney impairment (eGFR 15 to 59) receive a single 1 mg/kg dose. There is no approved oral dose.
2. Higher studied dose
The label says lower or greater doses than 1 mg/kg are not recommended, and single doses of 3 mg/kg or more of methylene blue products have caused low blood pressure, wheezing and reduced oxygen levels. In off-label research by mouth, trials used 195 mg a day for 6 months (bipolar disorder), 300 mg a day (a 1980s bipolar trial) and a single 260 mg dose (claustrophobia and PTSD studies). These were research doses, not recommendations.
3. Timing
Given once, with one possible repeat after an hour, during treatment for methemoglobinemia
4. With food
Not applicable for the approved injection
5. Split dosing
Not applicable; the label allows at most 2 doses for one episode in most cases
6. How long to try
A single episode of treatment. The label advises not taking serotonergic drugs within 72 hours after the last dose; your prescriber decides how any of your medicines are handled

What to track

Agitation, confusion, fast heartbeat, sweating, fever, muscle twitching or stiffness after a dose, which can be serotonin syndrome (seek emergency care)
Dark urine, yellow skin or eyes, tiredness or shortness of breath in the days after treatment, which can signal hemolysis
Rash, swelling or trouble breathing (allergic reaction: seek emergency care)
Confusion, dizziness or vision changes: the label advises not driving or operating machinery until these resolve
Blue urine is expected; it can also distort some urine tests and pulse oximeter readings

Bottom line: An intravenous hospital treatment at 1 mg/kg set by your prescriber; there is no approved oral dose, and serotonergic medicines and G6PD deficiency are the key dangers.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

In the label's adult studies (31 patients): headache, low potassium, diarrhea, low magnesium, muscle jerks (myoclonus), nausea and seizure-like episodes (each in 2% or more)Blue urine, because the dye passes into the urine; it can interfere with urine dipstick testsConfusion, dizziness and blurred visionReactions where the infusion goes in, such as swelling, hardening or itching, or leakage of the infusion under the skin

Serious risks

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: the ProvayBlue label says it may cause fetal harm and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Injection of a methylene blue product into the amniotic fluid during the second trimester was associated with intestinal atresia (a blocked bowel) in newborns and fetal death, and methylene blue given by mouth to pregnant rats and rabbits caused harm to the developing young. After injection into the amniotic fluid near birth, or treatment of a pregnant woman at term, the newborn should be watched for jaundice, hemolytic anemia, methemoglobinemia, breathing problems and light sensitivity. Breastfeeding: there is no information on whether methylene blue passes into human milk; because of possible serious effects, including damage to genetic material, the label says to stop breastfeeding during treatment and for up to 8 days afterward.

Interactions

SSRIs, SNRIs and MAOI antidepressants (for example sertraline, fluoxetine, escitalopram, venlafaxine, duloxetine, phenelzine)Critical

Boxed warning: methylene blue appears to block MAO, and with these antidepressants it has caused serotonin syndrome, sometimes fatal. The label says to avoid the combination; if intravenous treatment cannot be avoided, the lowest dose is used and the person is watched closely for up to 4 hours. Never take an oral methylene blue product with these medicines; your prescriber decides how your antidepressant is handled.

Opioids (for example tramadol, oxycodone, fentanyl)Critical

The boxed warning names opioids: methylene blue may cause serious or fatal serotonin syndrome with them, and the label says to avoid the combination. Tell every prescriber and pharmacist if you use methylene blue in any form.

Bupropion, buspirone, clomipramine, mirtazapine, linezolid and dextromethorphan (in many cough medicines)High

The label names these among medicines that enhance serotonin transmission and says to avoid using them with methylene blue because of the potential for serious nervous system reactions, including potentially fatal serotonin syndrome; it also says dextromethorphan may increase the risk. Linezolid is an antibiotic that also blocks MAO. Check cough and cold products with your pharmacist, and ask your prescriber or pharmacist before combining anything with methylene blue.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

ProvayBlue or generic methylene blue injection, 5 mg/mL, given intravenously by a healthcare provider
The FDA-approved prescribing information, which carries the boxed serotonin syndrome warning
A G6PD status check and a full medicine review before treatment when time allows

Be skeptical of…

"Nootropic", "brain booster" or "mitochondrial energy" supplement claims: no oral methylene blue product is FDA-approved, and the human brain studies are small and short
"Pharmaceutical grade" or "USP grade" on a dropper bottle presented as proof of safety for drinking: grade does not make a product an approved medicine or set a safe dose
"Anti-aging", "longevity" or "prevents Alzheimer's": the largest trial of a related drug did not slow Alzheimer's disease
"Safe with antidepressants" or no mention of serotonin syndrome: the approved label carries a boxed warning
No mention of G6PD deficiency, a contraindication

Frequently asked questions

Is oral methylene blue FDA-approved as a supplement?⌄

No. Every methylene blue product approved in Drugs@FDA is an injection given into a vein, such as ProvayBlue, used for methemoglobinemia. The drops, capsules and powders sold online for focus, energy or longevity are not FDA-approved drugs, and their strength and purity have not been reviewed by FDA.

Does methylene blue improve memory or brain function?⌄

The evidence is thin. One trial in 26 healthy adults found a single dose by mouth changed brain-scan activity and gave 7% more correct answers on a memory task an hour later. Small trials in bipolar depression found less depression and anxiety, but no improvement on cognitive tests. A large trial of a related drug did not slow Alzheimer's disease. No trial has tested the products sold online or long-term daily use.

Can I take methylene blue with my antidepressant?⌄

The label carries a boxed warning against using it with SSRIs, SNRIs and MAOIs, because methylene blue can cause serious or fatal serotonin syndrome with them. The label also says to avoid bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids and dextromethorphan with it. Do not combine an oral methylene blue product with these, and do not stop or change your antidepressant on your own: talk with your prescriber or pharmacist.

Why does G6PD deficiency matter?⌄

Methylene blue needs an NADPH-dependent enzyme to work, and people with G6PD deficiency make less NADPH in their red blood cells. The label says methylene blue is contraindicated in G6PD deficiency because it can cause severe hemolysis and severe anemia, and it may not even work. Ask your doctor whether you have been tested, especially if it runs in your family.

Can I take methylene blue with my supplements?⌄

Our interaction database has no supplement pairs for methylene blue yet, so this page lists only the medicine interactions from the label. Because the label warns about anything that enhances serotonin transmission, have a doctor or pharmacist review every supplement and medicine you take before any use.

Why did my urine turn blue?⌄

Methylene blue is a dye that passes into the urine, so blue or blue-green urine is expected. The label notes it can interfere with urine tests that rely on a blue indicator, and it can make pulse oximeter readings look lower than they are. Tell anyone testing you that you have had methylene blue.

References by claim

memory and attention in healthy adults (off-label)

Rodriguez et al., 2016 · PMC (2016) link

bipolar depression, added to other treatment (off-label)

Alda et al., 2017 · PubMed (2017) link

Naylor et al., 1986 · PubMed (1986) link

fear extinction in claustrophobia and PTSD therapy (off-label)

Telch et al., 2014 · PMC (2014) link

Zoellner et al., 2017 · PubMed (2017) link

Alzheimer's disease (LMTM, a related compound, not methylene blue itself)

Gauthier et al., 2016 · PMC (2016) link

Wischik et al., 2015 · PubMed (2015) link

Wischik et al., 2026 · PMC (2026) link

delirium after surgery in older adults (off-label, intravenous)

Zhang et al., 2025 · PMC (2025) link

Safety

ProvayBlue (methylene blue) injection prescribing information · DailyMed (FDA label) link

Zuschlag et al., 2018 · PubMed (2018) link

Urelle (methenamine, methylene blue and other ingredients) tablets, marketing category: unapproved drug other · DailyMed link

Track Methylene Blue with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 19, 2026·Evidence current as of Nov 19, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.